Annals of Clinical and Translational Neurology (Aug 2022)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder

  • Magnus Johnsson,
  • Fredrik Asztely,
  • Susanne Hejnebo,
  • Markus Axelsson,
  • Clas Malmeström,
  • Torbjörn Olausson,
  • Jan Lycke

DOI
https://doi.org/10.1002/acn3.51609
Journal volume & issue
Vol. 9, no. 8
pp. 1296 – 1301

Abstract

Read online

Abstract SARS‐COV‐2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotein‐associated disorder (MOGAD) has been recognized in patients with attacks of optic neuritis, myelitis, or encephalomyelitis and increased levels of anti‐MOG antibodies. The cause of MOGAD is unknown. However, there have been reports of single cases of MOGAD in patients with Covid‐19 infection. We report a series of SARS‐CoV‐2 positive patients that developed MOGAD, but a homology search did not support a cross‐reactive immune response to SARS‐CoV‐2 spike‐protein and MOG.